These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 39402973

  • 1. Immuno-PET Imaging of EGFR with 64Cu-NOTA Panitumumab in Subcutaneous and Metastatic Nonsmall Cell Lung Cancer Xenografts.
    Sarrami N, Wuest M, Paiva IM, Leier S, Lavasanifar A, Wuest F.
    Mol Pharm; 2024 Nov 04; 21(11):5797-5806. PubMed ID: 39402973
    [Abstract] [Full Text] [Related]

  • 2. Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
    Yamaguchi A, Achmad A, Hanaoka H, Heryanto YD, Bhattarai A, Ratianto, Khongorzul E, Shintawati R, Kartamihardja AAP, Kanai A, Sugo Y, S Ishioka N, Higuchi T, Tsushima Y.
    BMC Cancer; 2019 Oct 24; 19(1):1000. PubMed ID: 31651282
    [Abstract] [Full Text] [Related]

  • 3. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
    Boyle AJ, Cao PJ, Hedley DW, Sidhu SS, Winnik MA, Reilly RM.
    Nucl Med Biol; 2015 Feb 24; 42(2):71-7. PubMed ID: 25456837
    [Abstract] [Full Text] [Related]

  • 4. ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer.
    England CG, Jiang D, Hernandez R, Sun H, Valdovinos HF, Ehlerding EB, Engle JW, Yang Y, Huang P, Cai W.
    Mol Pharm; 2017 Oct 02; 14(10):3239-3247. PubMed ID: 28825843
    [Abstract] [Full Text] [Related]

  • 5. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer.
    Aghevlian S, Lu Y, Winnik MA, Hedley DW, Reilly RM.
    Mol Pharm; 2018 Mar 05; 15(3):1150-1159. PubMed ID: 29314858
    [Abstract] [Full Text] [Related]

  • 6. 64Cu-Labeled Trastuzumab Fab-PEG24-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents.
    Kwon LY, Scollard DA, Reilly RM.
    Mol Pharm; 2017 Feb 06; 14(2):492-501. PubMed ID: 28049295
    [Abstract] [Full Text] [Related]

  • 7. PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled Ramucirumab.
    Luo H, England CG, Graves SA, Sun H, Liu G, Nickles RJ, Cai W.
    J Nucl Med; 2016 Feb 06; 57(2):285-90. PubMed ID: 26541778
    [Abstract] [Full Text] [Related]

  • 8. Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [64Cu]Cu-NOTA-panitumumab F(ab')2 alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib.
    Boyle AJ, Cao PJ, Cai Z, Chan C, Hedley DW, Reilly RM.
    Nucl Med Biol; 2020 Feb 06; 84-85():46-54. PubMed ID: 32062317
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.
    Kumar SR, Gallazzi FA, Ferdani R, Anderson CJ, Quinn TP, Deutscher SL.
    Cancer Biother Radiopharm; 2010 Dec 06; 25(6):693-703. PubMed ID: 21204764
    [Abstract] [Full Text] [Related]

  • 10. Molecular imaging of platelet-derived growth factor receptor-alpha (PDGFRα) in papillary thyroid cancer using immuno-PET.
    Wagner M, Wuest M, Hamann I, Lopez-Campistrous A, McMullen TPW, Wuest F.
    Nucl Med Biol; 2018 Mar 06; 58():51-58. PubMed ID: 29367096
    [Abstract] [Full Text] [Related]

  • 11. Preclinical Evaluation of [64Cu]NOTA-CP01 as a PET Imaging Agent for Metastatic Esophageal Squamous Cell Carcinoma.
    Peng T, Wang X, Li Z, Bi L, Gao J, Yang M, Wang Y, Yao X, Shan H, Jin H.
    Mol Pharm; 2021 Sep 06; 18(9):3638-3648. PubMed ID: 34424706
    [Abstract] [Full Text] [Related]

  • 12. 64Cu-Labeled Repebody Molecules for Imaging of Epidermal Growth Factor Receptor-Expressing Tumors.
    Pyo A, Yun M, Kim HS, Kim TY, Lee JJ, Kim JY, Lee S, Kwon SY, Bom HS, Kim HS, Kim DY, Min JJ.
    J Nucl Med; 2018 Feb 06; 59(2):340-346. PubMed ID: 28916621
    [Abstract] [Full Text] [Related]

  • 13. Noninvasive Detection of HER2 Expression in Gastric Cancer by 64Cu-NOTA-Trastuzumab in PDX Mouse Model and in Patients.
    Guo X, Zhu H, Zhou N, Chen Z, Liu T, Liu F, Xu X, Jin H, Shen L, Gao J, Yang Z.
    Mol Pharm; 2018 Nov 05; 15(11):5174-5182. PubMed ID: 30251865
    [Abstract] [Full Text] [Related]

  • 14. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex.
    Ku A, Chan C, Aghevlian S, Cai Z, Cescon D, Bratman SV, Ailles L, Hedley DW, Reilly RM.
    Mol Pharm; 2019 Aug 05; 16(8):3559-3568. PubMed ID: 31242384
    [Abstract] [Full Text] [Related]

  • 15. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.
    Ping Li W, Meyer LA, Capretto DA, Sherman CD, Anderson CJ.
    Cancer Biother Radiopharm; 2008 Apr 05; 23(2):158-71. PubMed ID: 18454685
    [Abstract] [Full Text] [Related]

  • 16. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.
    Niu G, Li Z, Xie J, Le QT, Chen X.
    J Nucl Med; 2009 Jul 05; 50(7):1116-23. PubMed ID: 19525473
    [Abstract] [Full Text] [Related]

  • 17. Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice.
    Aghevlian S, Wu B, Raie MN, Tumbale SK, Kare AJ, Seo JW, Ferrara KW.
    Nucl Med Biol; 2021 Jul 05; 98-99():8-17. PubMed ID: 33962357
    [Abstract] [Full Text] [Related]

  • 18. Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies.
    Woo SK, Jang SJ, Seo MJ, Park JH, Kim BS, Kim EJ, Lee YJ, Lee TS, An GI, Song IH, Seo Y, Kim KI, Kang JH.
    J Nucl Med; 2019 Jan 05; 60(1):26-33. PubMed ID: 29777007
    [Abstract] [Full Text] [Related]

  • 19. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
    Bhattacharyya S, Kurdziel K, Wei L, Riffle L, Kaur G, Hill GC, Jacobs PM, Tatum JL, Doroshow JH, Kalen JD.
    Nucl Med Biol; 2013 May 05; 40(4):451-7. PubMed ID: 23454247
    [Abstract] [Full Text] [Related]

  • 20. Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody.
    Dearling JL, Voss SD, Dunning P, Snay E, Fahey F, Smith SV, Huston JS, Meares CF, Treves ST, Packard AB.
    Nucl Med Biol; 2011 Jan 05; 38(1):29-38. PubMed ID: 21220127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.